Drastic Au(111) reconstrucción de la superficie tras la adsorción del tripeptido del factor de crecimiento de la

Vincent Humblot1, Anne Vallée, Ahmed Naitabdi

  • 1Laboratoire de Réactivité de Surface, UMR CNRS 7197, Université Pierre et Marie Curie -UPMC Paris 6 case 178, 4 place Jussieu, 75005 Paris, France. vincent.humblot@upmc.fr

Resumen

La adsorción de las moléculas de tripeptido del factor de crecimiento de la insulina reconstruye dinámicamente la superficie del oro (Au) 111) a temperatura ambiente, sin necesidad de recocido. Este estudio revela un nuevo mecanismo de reestructuración de la superficie impulsado por moléculas.

Videos de Conceptos Relacionados

Insulin: The Receptor and Signaling Pathways01:28

Insulin: The Receptor and Signaling Pathways

Insulin action is mediated through a receptor tyrosine kinase, akin to the IGF-1 receptor. The number of receptors per cell varies significantly, from 40 on erythrocytes to 300,000 on adipocytes and hepatocytes. The insulin receptor consists of linked α/β subunit dimers, forming a heterotetramer glycoprotein with two extracellular α subunits and two β subunits spanning the membrane. The α subunits inhibit the inherent tyrosine kinase activity of the β subunits, but this inhibition is released...
Insulin Secretory Vesicles01:05

Insulin Secretory Vesicles

Insulin secretory vesicles release insulin to stimulate blood glucose uptake and regulate carbohydrate metabolism. When the blood glucose levels increase, glucose enters the pancreatic β-islet cells through glucose transporters. Once inside, glucose is metabolized through glycolysis, the citric acid cycle, and the electron transport chain, producing ATP. This increase in ATP concentration closes ATP-sensitive potassium channels, leading to depolarization of the membrane and the opening of...
Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...